uniQure (QURE) Insider Madhavan Balachandran Buys $292K of Stock

Insider Buying and Selling at uniQure N.V.

Madhavan Balachandran bought 11,685 shares of uniQure N.V. (NasdaqGS: QURE) for about $291,806 on June 17, 2026. The shares were purchased at a price of $24.97 each. This transaction shows a significant commitment from Balachandran, especially as the stock is currently priced at $45.77.

Recent Insider Transactions

Balachandran's purchase comes amid other insider activities at uniQure. CEO Matthew Kapusta also bought shares on the same day, purchasing 62,581 shares at $19.39 each, totaling about $1.21 million. Earlier, on June 24, Kapusta bought 4,128 shares at $31.71 each. In contrast, Chief Medical Officer Walid Abi-Saab sold 1,434 shares on June 26 for $67,197.24. These transactions reflect ongoing insider trading activity at the company.

How uniQure N.V. Stock Has Traded

uniQure's shares have seen considerable movement, currently trading at $45.77, well above their 52-week low of $8.73. The stock's price has increased significantly, especially compared to its previous close of $20.97. Investors are likely paying attention to this upward trend as the company prepares for its next earnings report.

Analysts Set New Price Targets

Analysts have recently adjusted their ratings on uniQure. On October 5, 2026, Barclays downgraded the stock to an Equal-Weight rating with a target of $28.00, down from $60.00. Conversely, RBC Capital maintained an Outperform rating with a target of $48.00 on October 2. Overall, the consensus rating remains a strong buy, with a mean price target of $61.46 based on 12 analyst opinions.

What uniQure N.V. Does

uniQure N.V. develops treatments for patients suffering from rare diseases. Its lead product candidate is AMT-130, a gene therapy for Huntington's disease, currently in clinical trials. The company is focused on innovative therapies, making insider purchases like Balachandran's noteworthy as they signal confidence in the company's future prospects.

What’s Next for uniQure

Looking ahead, investors will be watching for the upcoming earnings report scheduled for November 9, 2026. The recent insider purchases, including Balachandran's, may indicate confidence in the company's growth potential. It’s important to note that these insider transactions reflect past actions and may not represent current positions.